Abstract

Objective—To determine whether rapid clearance of interleukin 8 (IL-8) from plasma through binding to the erythrocyte chemokine receptor may be responsible for failure to detect IL-8 consistently after acute myocardial infarction.

Design—Plasma concentrations of IL-8 were measured at frequent intervals in 43 consecutive patients. In 21 of these, erythrocyte-bound IL-8 concentrations were also measured. The influence of infarct size, type of treatment, and the presence of early successful reperfusion on IL-8 release was assessed.

Results—Peak IL-8 concentrations in plasma were raised in 31 of the 43 patients (68%). Median plasma IL-8 concentrations were 16.0 pg/ml (range 2.4 to 225.0 pg/ml) six hours after the onset of chest pain. Twelve hours after the onset of symptoms, plasma IL-8 concentrations had already returned to normal in 27 patients. In contrast, in 18 of 21 patients (86%), erythrocyte-bound IL-8 concentrations were raised at between 6 and 30 hours, with a median peak value of 59.8 pg/ml (range 19 to 148 pg/ml). No correlation between peak creatine kinase MB and peak IL-8 (plasma or erythrocyte bound) was observed. There was a significant difference in peak plasma IL-8 concentrations between patients who underwent direct PTCA (19.4 pg/ml) and those who received conservative treatment (9.9 pg/ml; p = 0.0206), but no correlation with the presence of early successful reperfusion.

Conclusions—IL-8 is released in plasma after acute myocardial infarction and subsequently binds to red blood cells, resulting in only a transient rise of plasma IL-8 and a more prolonged increase of erythrocyte-bound IL-8.

Keywords: acute myocardial infarction; interleukin 8

Experimental models of acute ischaemic myocardial injury have indicated that with the onset of reperfusion an inflammatory response occurs, and this may contribute to tissue damage. Preventing the invasion of activated neutrophils in ischaemic–reperfused myocardium by blocking adhesion molecules on neutrophils or endothelium has been shown to limit infarct size in some, but not all, models of experimental myocardial infarction. Several cytokines, including tumour necrosis factor (TNF) and interleukin (IL) 6, play a role in activation of neutrophils, and circulating concentrations of these cytokines increase after acute myocardial infarction.

IL-8 plays an important role in mediating neutrophil invasion in a variety of inflammatory processes. Cellular sources of IL-8 include mononuclear phagocytes, neutrophils, and a wide variety of other cell types, including endothelial cells. High tissue concentrations of IL-8 are thought to enhance neutrophil adherence and transmigration, whereas circulating IL-8 prevents neutrophil emigration. Because IL-8, when bound to erythrocytes, is incapable of stimulating neutrophils, the erythrocyte chemokine receptor seems to function as a scavenger receptor, limiting IL-8 bioactivity. IL-8 induces upregulation of the leucocyte adhesion molecule CD11b/CD18 and therefore may play a key role in the pathogenesis of neutrophil induced reperfusion injury. In a canine model of myocardial ischaemia, reperfusion induced rapid and consistent induction of IL-8 mRNA expression. Antibodies directed against IL-8 blocked neutrophil-mediated cytotoxicity for cardiac myocytes. In addition, it has been suggested that IL-8 is a key participant in the cross talk between coagulation activation and cytokine cascades.

Therefore IL-8 release may be a useful marker of coagulation and inflammatory activation in acute myocardial infarction. However, previous reports on circulating IL-8 following acute myocardial infarction in humans have been controversial. Some investigators have shown raised plasma concentrations of IL-8 after acute myocardial infarction, but others have been unable to confirm the finding. These contradictory results may, at least partly, be explained by rapid clearance of circulating IL-8 from the plasma. One way by which IL-8 is cleared from the plasma is by binding to a multispecific chemokine receptor on erythrocytes. The erythrocyte chemokine receptor has been shown to be identical to the Duffy blood group antigen and is capable of binding IL-8, GROα, and several other chemokines, including RANTES (Regulated on Activation of Normal T cell Expressed and Secreted chemokine) and MCP-1 (monocyte chemoattractant protein 1). We recently described a method for the detection of erythrocyte-bound IL-8. In this study, we therefore investigated the time course and magnitude of both plasma and erythrocyte concentrations of IL-8.
Interleukin 8 released after acute myocardial infarction

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men 29 (67%)</td>
</tr>
<tr>
<td>Women 14 (33%)</td>
</tr>
<tr>
<td>Age (mean (SD)) 64 (13) years</td>
</tr>
<tr>
<td>Anterior AMI 15</td>
</tr>
<tr>
<td>Inferior AMI 23</td>
</tr>
<tr>
<td>Non-Q wave AMI 5</td>
</tr>
<tr>
<td>PTCA 14</td>
</tr>
<tr>
<td>Thrombolysis 17</td>
</tr>
<tr>
<td>Conservative 12</td>
</tr>
<tr>
<td>Successful reperfusion 26</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty.

Bound IL-8 release in patients with acute myocardial infarction. We also assessed the influence of infarct size, method of treatment, and early successful reperfusion on IL-8 release.

Methods

Patients were eligible for the study when presenting with chest pain of less than six hours' duration. Patients with infectious disease, fever on admission, or taking anti-inflammatory drugs (with the exception of aspirin) were excluded. The protocol was approved by the medical ethics committee of our institution and all patients gave informed consent.

Patients with ST elevation of at least 2 mm in two contiguous precordial leads, 1 mm ST elevation in two standard limb leads, or a previously unknown left bundle branch block were candidates for reperfusion treatment. All patients received aspirin 300 mg on admission. If an interventional cardiologist and a catheterisation laboratory were available and the time course was such that the infarct related vessel could be opened within six hours of the onset of symptoms, primary percutaneous transluminal coronary angioplasty (PTCA) was performed where there was electrocardiographic evidence of anterior acute myocardial infarction or inferior acute myocardial infarction with concomitant right ventricular infarction. Thrombolysis was started in all other patients eligible for reperfusion treatment. Patients received either accelerated rt-PA (alteplase) (Actilyse; Boehringer Ingelheim, Germany; dose according to GUSTO-I) or 1.5 x 10^6 units of streptokinase (KabiKarinasse; Kabi Pharmacia, Sweden). Thereafter, patients received unfractionated heparin intravenously with a target activated partial thromboplastin time of 60 to 90 seconds. β Blockers, calcium entry blockers, or other drugs were prescribed at the discretion of the attending physician. The final diagnosis of acute myocardial infarction was based on a history of typical ischaemic chest pain, characteristic ECG changes, and a typical rise and fall of creatine kinase (CK-MB) activity, with a peak exceeding 8 U/L.

Blood sampling and assays

Blood samples were collected from an antecubital vein on admission before any drugs were given, and at 4, 6, 8, 12, 16, 20, 24, 30, 36, 42, 48 hours after the onset of symptoms, in 4.5 ml EDTA Vacutainers for IL-8 and 4.5 ml lithium-heparin Vacutainers for CK-MB assay. EDTA blood was immediately placed on ice (4°C) and processed within 30 minutes. Blood samples were centrifuged for 20 minutes at 2000 g at 4°C and aliquots of plasma were stored at −20°C for IL-8 measurement. For determination of erythrocyte bound IL-8, erythrocytes were isolated by centrifugation over Polymorphprep (Nycomed Pharma, Norway). Erythrocyte fractions were then washed four times with saline (180 xg, 10 minutes) to remove residual platelets. The erythrocyte suspension was adjusted to the original packed cell volume, and the removal of leucocytes (<200/μl) and platelets (<700/μl) was confirmed (Coulter counter STKR, Coulter, Hialeah, Florida). The red blood cells were lysed by adding Triton X-100 at a final concentration of 0.1% and the lysates stored at −20°C.

IL-8 concentrations in plasma and erythrocyte lysates were measured with a commercial enzyme linked immunosorbent assay kit (Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, CLB, Amsterdam, The Netherlands), with a lower detection limit of 1.0 pg/ml. Plasma concentrations of IL-8 in healthy individuals are below 10 pg/ml (manufacturer's product information). The presence of the Triton X-100 did not interfere with the detection of IL-8 in the assay. Since normal values for erythrocyte bound IL-8 were not available, concentrations of erythrocyte bound IL-8 were determined in 50 healthy volunteers.

Reperfusion

Reperfusion status was assessed by angiography in patients who underwent primary PTCA. To assess successful reperfusion non-invasively in patients who received thrombolytic treatment, hourly changes on the ECG and clinical signs were monitored. Successful reperfusion was defined by the presence of the following conditions: (1) the symptoms of chest pain improved, whether or not this was preceded by an episode of reperfusion arrhythmia (accelerated idioventricular rhythm or sinus bradycardia); (2) there was a concomitant reduction in ST elevation of at least 50%; (3) peak CK-MB occurred at or before 12 hours after the onset of symptoms. In all other cases attempted reperfusion was considered unsuccessful.

Table 2 Peak values of IL-8 in plasma and of erythrocyte bound IL-8

<table>
<thead>
<tr>
<th>Plasma (n=43)</th>
<th>Erythrocyte bound (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTCA 19.4 (5.8 to 165)*</td>
<td>49.9 (18.7 to 120.1)</td>
</tr>
<tr>
<td>Thrombolysis 19.1 (2.4 to 224)</td>
<td>61.7 (22.2 to 148)</td>
</tr>
<tr>
<td>Conservative 9.9 (4.3 to 30.6)*</td>
<td>61.1 (23 to 142.0)</td>
</tr>
<tr>
<td>Reperfusion 16.6 (2.4 to 224)</td>
<td>58.5 (18.7 to 120)</td>
</tr>
<tr>
<td>No reperfusion 14.9 (5.6 to 62.1)</td>
<td>60.2 (23 to 148)</td>
</tr>
</tbody>
</table>

Values are medians (range) in pg/ml. Differences between groups were tested with the Mann-Whitney U test for non-normally distributed data.

*Difference between plasma IL-8 in the PTCA group v the conservative group, p=0.0206. Other differences between groups were not significant.
STATISTICAL ANALYSIS
Median and ranges for peak values of plasma and erythrocyte bound IL-8 are reported. Differences between groups were tested by the Mann-Whitney U test. Correlations between peak CK-MB and peak IL-8 were assessed with linear regression and Pearson's correlation. A p value of less than 0.05 was considered statistically significant. Values are given as mean (SD) or median (range).

RESULTS

PATIENTS
Forty-three consecutive patients were included in the study. Patient characteristics are summarised in table 1, which shows a distribution of gender, age, and infarct location representative of patients with acute myocardial infarction. Fourteen patients underwent direct PTCA, 17 received thrombolytic treatment (alteplase, n = 9; streptokinase, n = 8), and 12 were treated conservatively.

PLASMA IL-8
Plasma IL-8 concentrations were increased in 31 patients (68%) and peaked early, usually at six hours after the onset of symptoms. In 27 patients (63%), plasma IL-8 declined to normal values within 12 hours. Median peak IL-8 concentrations in plasma were 15.5 (40) pg/ml (range 2.4 to 225). No correlation was apparent between peak plasma IL-8 and peak CK-MB, as shown in the scatterplot in fig 1 (r² = 0.009; p = 0.54). There was no difference in peak plasma IL-8 concentrations between patients with and without early successful reperfusion (table 2); however, there was a significant difference in peak plasma IL-8 between the PTCA group and the conservative group (p = 0.02, table 2).

ERYTHROCYTE BOUND IL-8
In 50 healthy controls, mean erythrocyte bound IL-8 was 15.7 (8.2) pg/ml (upper limit of normal = 32 pg/ml). Erythrocyte bound IL-8 concentrations were measured in 21 patients with acute myocardial infarction and was found to be 4.4 (1.3) times higher than simultaneous plasma IL-8 concentrations, as shown in fig 2. In 18 of 21 patients (86%), peak erythrocyte bound IL-8 concentrations were above normal. Interestingly, in three of these patients plasma concentrations of IL-8 were normal (<10 pg/ml). Median peak erythrocyte bound IL-8 was 59.8 pg/ml (range 19 to 148). Erythrocyte bound IL-8 concentrations were raised from 6 to 30 hours, with peak values at 20 hours after the onset of symptoms. Erythrocyte bound IL-8 comprised 85(8)% of total IL-8 per ml of whole blood. Peak erythrocyte bound IL-8 and peak CK-MB were not correlated (r² = 0.001; p = 0.889). Moreover, peak levels of erythrocyte bound IL-8 were not correlated with treatment or with early successful reperfusion.

Discussion
This study confirms that IL-8 is released following acute myocardial infarction. In our study, plasma concentrations of IL-8 were raised in 68% of patients with myocardial infarction. Moreover, we showed that approximately 85% of IL-8 in whole blood is bound by erythrocytes. Measurement of erythrocyte bound IL-8 is time consuming, requires immediate processing of fresh blood samples, and depends on the interplay between dedicated nursing staff and laboratory facilities. We were therefore only able to measure erythrocyte bound IL-8 concentrations in 21 of the 43 patients. Raised concentrations of erythrocyte bound IL-8 were found in 18 of these 21 patients (86%), three of whom had normal plasma IL-8 values.

Plasma IL-8 concentrations increased with an early peak at six hours after the onset of symptoms, and returned to normal values within 12 hours in the majority of patients. Abe et al also showed an early release of IL-8 in plasma after acute myocardial infarction in a
small group of five patients. Similarly, Kanda et al. found peak values at 4.4 (1.2) hours after admission, which rapidly returned to normal in 24 patients. Moreover, these investigators found normal plasma concentrations of IL-8 in 33% of their patients, which is similar to the proportion of patients with normal IL-8 values in our study. In contrast, Siminak et al. failed to show IL-8 release after acute myocardial infarction.

Our data suggest that IL-8 released after acute myocardial infarction is rapidly cleared from the plasma through binding to a chemokine scavenger receptor on erythrocytes. Indeed, binding of IL-8 to red blood cells has been shown previously. Hence failure to demonstrate IL-8 in plasma of patients following acute myocardial infarction may be due to this clearance mechanism.

When bound to erythrocytes, IL-8— and most probably other chemokines—is incapable of stimulating its normal target cells. Since IL-8 may play an important role in transendothelial neutrophil migration induced by ischemia/reperfusion, binding of IL-8 by erythrocytes may thus prevent neutrophil activation at sites other than the site of injury. The importance of this pathway has been questioned, since a large population of healthy individuals do not express Duffy antigen. Recently, however, it has been shown that postcapillary endothelial cells of these Duffy negative individuals do express Duffy antigen, but the functional importance of Duffy antigen expressed by endothelial cells—including a potential role as chemokine scavenger—remains to be determined.

In the present study, peak CK-MB values did not correlate with peak concentrations of plasma or erythrocyte bound IL-8. Although there was a significant difference in peak plasma IL-8 concentrations between patients who underwent direct PTCA and patients who were treated conservatively, no difference was found in peak erythrocyte bound IL-8 values between these two groups. Reperfusion status was assessed by angiography or non-invasively, as described previously. Early successful reperfusion did not correlate with peak values of IL-8. This is somewhat surprising and in contrast to a report showing lower CRP and IL-6 values after successful reperfusion. However, minor differences or rapid changes in IL-8 released locally in the coronary vascular tree may be undetectable in the peripheral circulation.

We conclude that IL-8 is increased in plasma in about 70% of patients with acute myocardial infarction. Plasma IL-8 peaks early and returns to normal values in the majority of patients within 12 hours. In contrast, increased concentrations of erythrocyte bound IL-8 are found in 86% of patients with acute myocardial infarction. Erythrocyte bound IL-8 values peak later and remain elevated for longer. Although there was a small difference in plasma IL-8 concentrations between patients treated with PTCA and patients treated conservatively, IL-8 release after acute myocardial infarction appears not to be determined by infarct size, successful early reperfusion, or method of treatment.

We thank the medical and nursing staff of the coronary care unit of the Academic Medical Centre for their efforts and enthusiasm in performing this study, which was supported in part by a grant of the Dutch Heart Foundation (92-72).


